(480) 821-2838

(QOPI) Certification program, an affiliate of the American Society of Clinical Oncology - Learn More

Open Trials

Breast Cancer Trials:

Advanced HER2 – HR + Breast Cancer

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
For questions please contact 480-398-7671

Advanced or metastatic HER2– ER+ Breast Cancer

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)
For questions, please contact 480-398-7671

Advanced or metastatic HER2 positive Breast Cancer

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)
For questions, please contact 480-398-7671

Previously treated metastatic HER2+Breast Cancer

Previously treated metastatic HER2+ Breast Cancer. A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment.
For questions, please contact 480-398-7671

Gynecologic Trials:

Previously treated serous epithelial ovarian, fallopian tube, or peritoneal cancer

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
For questions please contact 480-398-7671

Leukemia Trials:

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL)
For questions, please contact 480-398-7671

Patients previously treated on another clinical trial

An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
For questions, please contact 480-398-7671

Lung Cancer Trials:

2nd or 3rd line treatment for Non-Small Cell Lung Cancer (NSCLC) after prior platinum-based chemotherapy
Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)
For questions please contact 480-398-7671

Lymphoma Trials:

Previously treated Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma
For questions, please contact 480-398-7671

Lung Cancer Trials:

Fully resected Non-Small Cell Lung Cancer (NSCLC)

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
For questions please contact 480-398-7671

Small cell lung cancer (SCLC) with one prior chemotherapy

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/ Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line
For questions, please contact 480-398-7671

Melanoma Trials:

Maintenance Treatment for Patients with Resected Stage IIB, IIC, or III Melanoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence.
For questions, please contact 480-398-7671

Multiple Myeloma Trials:

Treatment for refractory or relapsed multiple myeloma

A Phase III Study of Pomalidomide and low dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM)
For questions, please contact 480-398-7671

Prostate Cancer Trials:

Hormone-sensitive prostate cancer

A Randomized, Double-blind, Placebo Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer
For questions please contact 480-398-7671

Localized or locally advanced Prostate Cancer receiving radiation

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
For questions please contact 480-398-7671

First line chemotherapy for metastatic castrate-resistant prostate cancer

A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
For questions, please contact 480-398-7671

Renal Cell Cancer Trials:

Renal Cell Cancer

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)
For questions please contact 480-398-7671

Urothelial Cancer Trials:

Advanced or metastatic urothelial carcinoma of the renal pelvis, uterer, bladder, or urethra

Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial Carcinoma
For questions, please contact 480-398-7671